Type
Internal restructuring
Country
Ireland
Region
Southern and Eastern; Dublin;
Location of affected unit(s)
Dublin
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

400 jobs
Number of planned job losses
Job loss
Announcement Date
13 October 2022
Employment effect (start)
13 October 2022
Foreseen end date
31 October 2024

Description

Novartis, a Swiss multinational pharmaceutical group has announced it will cut approximately 400 jobs at its Dublin office over the next two years. The company currently employs 1,000 people at its global service centre in Dublin and 500 people in Cork, however these jobs are unaffected.

The job cuts are part of a global restructuring to cut costs by $1 billion (€1.03bn). As part of this restructuring the company announced in early 2022, that it was to cut 8,000 jobs globally, or 7% of its 108,000-strong workforce.

Previous factsheets for Novartis have been recorded in the ERM database in 2022, with an announced global restructuring affecting 8000 employees globally (Novartis-2022-WO), and  the corresponding restructuring in Belgium (Novartis-2022-BE) and Spain (Novartis-2022-ES).


Sources

Citation

Eurofound (2022), Novartis, Internal restructuring in Ireland, factsheet number 107688, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/107688.